## 2025 APEC GRM CoE Workshop Agenda (draft)

TOPICS         Opening Remarks         elcome Remarks & Opening Remarks &         roup Photo         PWA Introduction         09:30-09:45 GRM Relocate         fine the core competency of applicate         TFDA	TFDA/PMDA/APAC e to Room 402CD nts & reviewers Apurva Uniyal	Room           401           402CD		
elcome Remarks & Opening Remarks & roup Photo PWA Introduction <u>09:30-09:45 GRM Relocate</u> fine the core competency of applicate TFDA	TFDA/PMDA/APAC e to Room 402CD nts & reviewers Apurva Uniyal			
roup Photo PWA Introduction <u>09:30-09:45 GRM Relocate</u> fine the core competency of applican TFDA	e to Room 402CD nts & reviewers Apurva Uniyal	402CD		
fine the core competency of applicat TFDA	nts & reviewers Apurva Uniyal	402CD		
TFDA	Apurva Uniyal	402CD		
efine the core competency of applicants				
reviewers	Regulatory Innovation Research Scient D. K. Kim International Center for Reg Science, Department of Regulatory and of Southern Sciences, University of So California (USC)	gulatory d Quality		
Session 2-1: Managing and conducting the review402Focusing on implementation of pathways for approval of drugs for unmet medical needs and its outcomes402[Moderator] TFDA402				
sperience sharing for accelerated approval US	Former US FDA officer (TBC)			
perience sharing for Conditional arketing Authorisation by EMA	Margaux PHILIPPE Scientific Specialist, Oncology & Radiopharmaceuticals Office, Human Medicines Division, European Medicir Agency (EMA)	ies		
12:00-13:00 Lunch Time				
Session 2-2: Managing and conducting the review40Focusing on implementation of pathways for approval of drugs for unmet medical needs and its outcomes40[Moderator] Apurva Uniyal Regulatory Innovation Research Scientist, The D. K. Kim40International Center for Regulatory Science, Department of Regulatory and Quality of Southern40				
	hentation of pathways for approval of drugs for <b>FDA</b> berience sharing for accelerated approval US berience sharing for Conditional cketing Authorisation by EMA 12:00-13:00 Lunc anaging and conducting the review hentation of pathways for approval of drugs for Apurva Uniyal Regulatory Innovation R	Anaging and conducting the review         nentation of pathways for approval of drugs for unmet medical needs and its outcomes         FDA         berience sharing for accelerated approval         JS         berience sharing for Conditional         cketing Authorisation by EMA         12:00-13:00 Lunch Time         anaging and conducting the review         nentation of pathways for approval of drugs for unmet medical needs and its outcomes         Appriva Uniyal Regulatory Innovation Research Scientist, The D. K. Kim         er for Regulatory Science, Department of Regulatory and Quality of Southern		

13:00-13:20 13:20-13:40	Principles of accelerated approval by TFDA Experience sharing for conditional early approval by PMDA	TFDA PMDA	
13:40-14:00	Panel Discussion	TBD	
14:00-14:15 Coffee Break			
Session 3: Planning of Application [Moderator] IRPMA		402CD	
14:15-15:15	<ul> <li>Introductory Lectures</li> <li>Planning for Submission for NDA with unmet medical needs</li> <li>Planning for Submission for LEX, biosimilar with unmet medical needs</li> </ul>	[ Speaker ] IRPMA [ Facilitator ] TFDA/CDE/APAC/IRPMA	
15:15-16:15	Group Discussion		
16:15-17:15	Group Presentation		
17:15-17:20	Take Home Message		
1	1720-1730 Relocate to 1F (LIYAN internatio	nal banquet restaurant)	1F
17:30-19:30	Welcome Reception		

Wednesday, August 27 (DAY 2) - Room 402CD				
TIME	TOPICS	AFFILIATION		
Session 4: Preparation of Application Dossier Innovating for the Future: Preparing Your Applications [Moderator] JPMA				
09:00-10:00	<ul> <li>Introductory Lectures</li> <li>Current Environment</li> <li>Preparation of Application Dossier based on GsubP</li> </ul>	[ Speaker ] JPMA [ Facilitator ] TFDA/CDE/APAC/IRPMA		
10:00-10:15 Coffee Break				
10:15-11:00	Group Discussion			
11:00-11:55	Group Presentation			
11:55-12:00	Take Home Message			
12:00-13:00 Lunch Time				
Session 5: Experience sharing for implementation of pathways for approval of drugs for unmet medical needs in 3 Economies [Moderator] TFDA				
13:00-13:20	Economies 1	TBD		
13:20-13:40	Economies 2	TBD		
13:40-14:00	Economies 3	TBD		
14:00-14:20	Q&A	TBD		
14:20-14:35 Coffee Break				
Session 6: Communications [Moderator] Min Chen Former Acting Director of Division of Pharmacovigilance, Office of Surveillance and Epidemiology, CDER, US FDA				
14:35-15:35	Communications for submission and review of drugs for unmet medical needs	<b>[ Speaker ]</b> <b>Min Chen</b> Former Acting Director of Division of		

15:35-16:35	Group Discussion	Pharmacovigilance, Office of
16:35-17:35	Group Presentation	Surveillance and Epidemiology, CDER, US FDA
17:35-17:40	Take Home Message	JPMA [Facilitator] TFDA/CDE/APAC/IRPMA

Thursday, August 28 (DAY 3) - Room 402CD				
TIME	TOPICS	AFFILIATION		
Session 7: Crit	Session 7: Critical Thinking and Regulatory Decision-making			
[Moderator]	TFDA			
09:00-10:00	An overview of regulatory strategies for	Chi-Hsun Chen		
	products with unmet medical needs &	Senior Clinical Section Chief, Center for		
	Cases demonstration	Drug Evaluation		
Session 8: Special Lecture				
[Moderator]	TFDA			
10:00-10:30	An overview of managing and conducting the review for drug-device combination products (Regulator)	PMDA		
10:30-11:00	Experience sharing for success in regulatory approval of drug-device combination products (Industry)	<b>Christian Andreas Emmendörffer</b> (TBC) Principal Regulatory Program Director, Roche Pharma LTD		
11:00-11:30 Coffee Break				
Closing Remarks				
11:30-12:15	Certificate Award Ceremony			
12:15-12:30	Closing Remarks	TFDA		